STERIS plc STE
Verdict: Sell. Fair value $204 against a price of $261 on 6 Jan 2026, 22% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: There is a significant and persistent divergence between Operating Cash Flow and Net Income (2025:.... The OCF / Net Income ratio has declined from an exceptionally high 7.07 in 2023 to 2.57 in 2024 and....
Main risks
- Mediocre Return on Capital: ROE (9.2%) and ROIC (9.2%) are below industry averages, and the estimated 3-year ROIIC of 9.2% suggests questionable capital allocation efficiency on recent investments.
- Volatile Net Income: Annual net income has shown significant volatility ($0.24B in 2022, $0.11B in 2023, $0.61B in 2025), indicating potential instability in bottom-line profitability despite top-line growth.
- Data Gaps and Proxy Reliance: Critical metrics like ROIC and ROIIC rely on proxies for EBIT and historical invested capital due to missing data, reducing the confidence level of the capital efficiency assessment.
- There is a significant and persistent divergence between Operating Cash Flow and Net Income (2025:...
- Valuation prices in optimistic scenario (limited margin for error)
- There is a significant and persistent divergence between Operating Cash Flow and Net Income (2025: $540M, 2024: $590M, 2023: $650M). This causes extreme volatility in reported Net Income (from $0.11B in 2023 to $0.61B in 2025) despite steady revenue growth. This suggests GAAP earnings are heavily influenced by large, recurring non-cash expenses (like amortization of acquisition-related intangibles, restructuring, or impairments) that obscure the company's core operational profitability.